IBDEI0AQ ; ; 20-FEB-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 20, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14246,1,5,0)
 ;;=5^Vit B12 Deficiency (Pernicious Anemia)
 ;;^UTILITY(U,$J,358.3,14246,2)
 ;;=^7161
 ;;^UTILITY(U,$J,358.3,14247,0)
 ;;=282.60^^107^871^108
 ;;^UTILITY(U,$J,358.3,14247,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14247,1,4,0)
 ;;=4^282.60
 ;;^UTILITY(U,$J,358.3,14247,1,5,0)
 ;;=5^Sickle-Cell Anemia
 ;;^UTILITY(U,$J,358.3,14247,2)
 ;;=^7188
 ;;^UTILITY(U,$J,358.3,14248,0)
 ;;=282.62^^107^871^109
 ;;^UTILITY(U,$J,358.3,14248,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14248,1,4,0)
 ;;=4^282.62
 ;;^UTILITY(U,$J,358.3,14248,1,5,0)
 ;;=5^Sickle-Cell With Crisis
 ;;^UTILITY(U,$J,358.3,14248,2)
 ;;=^267982
 ;;^UTILITY(U,$J,358.3,14249,0)
 ;;=281.1^^107^871^122
 ;;^UTILITY(U,$J,358.3,14249,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14249,1,4,0)
 ;;=4^281.1
 ;;^UTILITY(U,$J,358.3,14249,1,5,0)
 ;;=5^Vit B12 Deficiency(Dietary)
 ;;^UTILITY(U,$J,358.3,14249,2)
 ;;=^267974
 ;;^UTILITY(U,$J,358.3,14250,0)
 ;;=286.7^^107^871^51
 ;;^UTILITY(U,$J,358.3,14250,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14250,1,4,0)
 ;;=4^286.7
 ;;^UTILITY(U,$J,358.3,14250,1,5,0)
 ;;=5^Coagulation Defect(Any),Acquired
 ;;^UTILITY(U,$J,358.3,14250,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,14251,0)
 ;;=289.9^^107^871^118
 ;;^UTILITY(U,$J,358.3,14251,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14251,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,14251,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,14251,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,14252,0)
 ;;=451.9^^107^871^119
 ;;^UTILITY(U,$J,358.3,14252,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14252,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,14252,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,14252,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,14253,0)
 ;;=446.6^^107^871^120
 ;;^UTILITY(U,$J,358.3,14253,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14253,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,14253,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(TTP)
 ;;^UTILITY(U,$J,358.3,14253,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,14254,0)
 ;;=286.4^^107^871^123
 ;;^UTILITY(U,$J,358.3,14254,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14254,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,14254,1,5,0)
 ;;=5^Von Willebrand'S Disease
 ;;^UTILITY(U,$J,358.3,14254,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,14255,0)
 ;;=204.00^^107^871^6
 ;;^UTILITY(U,$J,358.3,14255,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14255,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,14255,1,5,0)
 ;;=5^All, W/O Remission
 ;;^UTILITY(U,$J,358.3,14255,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,14256,0)
 ;;=204.01^^107^871^5
 ;;^UTILITY(U,$J,358.3,14256,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14256,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,14256,1,5,0)
 ;;=5^All, In Remission
 ;;^UTILITY(U,$J,358.3,14256,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,14257,0)
 ;;=204.10^^107^871^48
 ;;^UTILITY(U,$J,358.3,14257,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14257,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,14257,1,5,0)
 ;;=5^Cll, W/O Remission
 ;;^UTILITY(U,$J,358.3,14257,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,14258,0)
 ;;=204.11^^107^871^47
 ;;^UTILITY(U,$J,358.3,14258,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14258,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,14258,1,5,0)
 ;;=5^Cll, In Remission
 ;;^UTILITY(U,$J,358.3,14258,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,14259,0)
 ;;=202.41^^107^871^73
 ;;^UTILITY(U,$J,358.3,14259,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14259,1,4,0)
 ;;=4^202.41
 ;;^UTILITY(U,$J,358.3,14259,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspec Site
 ;;^UTILITY(U,$J,358.3,14259,2)
 ;;=^267472
 ;;^UTILITY(U,$J,358.3,14260,0)
 ;;=201.90^^107^871^80
 ;;^UTILITY(U,$J,358.3,14260,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14260,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,14260,1,5,0)
 ;;=5^Hodgkin'S Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,14260,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,14261,0)
 ;;=785.6^^107^871^86
 ;;^UTILITY(U,$J,358.3,14261,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14261,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,14261,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,14261,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,14262,0)
 ;;=200.20^^107^871^87
 ;;^UTILITY(U,$J,358.3,14262,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14262,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,14262,1,5,0)
 ;;=5^Lymphoma, Burkitt'S, Unspecified Sites
 ;;^UTILITY(U,$J,358.3,14262,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,14263,0)
 ;;=202.00^^107^871^89
 ;;^UTILITY(U,$J,358.3,14263,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14263,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,14263,1,5,0)
 ;;=5^Lymphoma, Low-Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,14263,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,14264,0)
 ;;=200.10^^107^871^88
 ;;^UTILITY(U,$J,358.3,14264,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14264,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,14264,1,5,0)
 ;;=5^Lymphoma, Int Or High Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,14264,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,14265,0)
 ;;=273.3^^107^871^90
 ;;^UTILITY(U,$J,358.3,14265,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14265,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,14265,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,14265,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,14266,0)
 ;;=203.00^^107^871^99
 ;;^UTILITY(U,$J,358.3,14266,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14266,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,14266,1,5,0)
 ;;=5^Multiple Myeloma W/O Rem
 ;;^UTILITY(U,$J,358.3,14266,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,14267,0)
 ;;=203.01^^107^871^98
 ;;^UTILITY(U,$J,358.3,14267,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14267,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,14267,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,14267,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,14268,0)
 ;;=238.6^^107^871^102
 ;;^UTILITY(U,$J,358.3,14268,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14268,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,14268,1,5,0)
 ;;=5^Plasmacytoma Nos
 ;;^UTILITY(U,$J,358.3,14268,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,14269,0)
 ;;=205.00^^107^871^8
 ;;^UTILITY(U,$J,358.3,14269,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14269,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,14269,1,5,0)
 ;;=5^Aml, W/O Remission
 ;;^UTILITY(U,$J,358.3,14269,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,14270,0)
 ;;=205.01^^107^871^7
 ;;^UTILITY(U,$J,358.3,14270,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14270,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,14270,1,5,0)
 ;;=5^Aml, In Remission
 ;;^UTILITY(U,$J,358.3,14270,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,14271,0)
 ;;=205.10^^107^871^50
 ;;^UTILITY(U,$J,358.3,14271,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14271,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,14271,1,5,0)
 ;;=5^Cml, W/O Remission
 ;;^UTILITY(U,$J,358.3,14271,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,14272,0)
 ;;=205.11^^107^871^49
 ;;^UTILITY(U,$J,358.3,14272,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14272,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,14272,1,5,0)
 ;;=5^Cml, In Remission
 ;;^UTILITY(U,$J,358.3,14272,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,14273,0)
 ;;=289.0^^107^871^52
 ;;^UTILITY(U,$J,358.3,14273,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14273,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,14273,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,14273,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,14274,0)
 ;;=238.4^^107^871^103
 ;;^UTILITY(U,$J,358.3,14274,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14274,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,14274,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,14274,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,14275,0)
 ;;=V58.61^^107^871^124
 ;;^UTILITY(U,$J,358.3,14275,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14275,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,14275,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,14275,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,14276,0)
 ;;=282.49^^107^871^116
 ;;^UTILITY(U,$J,358.3,14276,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14276,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,14276,1,5,0)
 ;;=5^Thalassemia Nec
 ;;^UTILITY(U,$J,358.3,14276,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,14277,0)
 ;;=289.89^^107^871^18
 ;;^UTILITY(U,$J,358.3,14277,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14277,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,14277,1,5,0)
 ;;=5^Blood Diseases Nec
 ;;^UTILITY(U,$J,358.3,14277,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,14278,0)
 ;;=238.79^^107^871^85
 ;;^UTILITY(U,$J,358.3,14278,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14278,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,14278,1,5,0)
 ;;=5^Lymph/Hematpoitc Tis Nec
 ;;^UTILITY(U,$J,358.3,14278,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,14279,0)
 ;;=287.30^^107^871^104
 ;;^UTILITY(U,$J,358.3,14279,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14279,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,14279,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,14279,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,14280,0)
 ;;=288.09^^107^871^4
 ;;^UTILITY(U,$J,358.3,14280,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14280,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,14280,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,14280,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,14281,0)
 ;;=284.81^^107^871^15
 ;;^UTILITY(U,$J,358.3,14281,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14281,1,4,0)
 ;;=4^284.81
 ;;^UTILITY(U,$J,358.3,14281,1,5,0)
 ;;=5^Aplastic Due To Drugs
 ;;^UTILITY(U,$J,358.3,14281,2)
 ;;=^335245
 ;;^UTILITY(U,$J,358.3,14282,0)
 ;;=284.89^^107^871^14
 ;;^UTILITY(U,$J,358.3,14282,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14282,1,4,0)
 ;;=4^284.89
 ;;^UTILITY(U,$J,358.3,14282,1,5,0)
 ;;=5^Aplastic Anemia due to Chr disease
 ;;^UTILITY(U,$J,358.3,14282,2)
 ;;=^87880
 ;;^UTILITY(U,$J,358.3,14283,0)
 ;;=284.9^^107^871^12
 ;;^UTILITY(U,$J,358.3,14283,1,0)
 ;;=^358.31IA^5^2
